Results 1 to 10 of about 9,828 (193)

Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial

open access: yesEBioMedicine, 2015
Background: Abnormalities in membrane excitability and Na+ channel function are characteristic of amyotrophic lateral sclerosis (ALS). We aimed to examine the neuroprotective potential, safety and tolerability of the Na+ channel blocker and membrane ...
Steve Vucic, Susanna B Park
exaly   +4 more sources

Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action [PDF]

open access: yesCells, 2021
Cardiac ryanodine receptor (RyR2) mutations are implicated in the potentially fatal catecholaminergic polymorphic ventricular tachycardia (CPVT) and in atrial fibrillation.
Samantha C. Salvage   +4 more
doaj   +8 more sources

The Frontal QRS-T Angle Remains Unchanged in Patients Without Structural Heart Disease Receiving Flecainide Therapy [PDF]

open access: yesJournal of Cardiovascular Development and Disease
Introduction: Prolongation of the QT interval and QRS duration, which are markers of ventricular repolarization and depolarization, has been reported in patients receiving flecainide therapy.
Mehmet Kucukosmanoglu   +4 more
doaj   +2 more sources

Flecainide- and isoproterenol-induced alterations in heart rate variability and DFA-derived physiological complexity in anesthetized mice [PDF]

open access: yesBMC Cardiovascular Disorders
Background Heart rate variability (HRV) provides insight into cardiac autonomic regulation, while nonlinear HRV indices may capture dynamic features of cardiac rhythm that are not fully reflected by conventional time- and frequency-domain parameters ...
Hasan Fehmi Ozel   +3 more
doaj   +2 more sources

Flecainide in Structural Heart Disease: Reconsidering Its Role in Contemporary Arrhythmia Management [PDF]

open access: yesLife
Background: Flecainide has remained largely excluded from use in structural heart disease for more than three decades, mainly because of the Cardiac Arrhythmia Suppression Trial, which showed excess mortality in post-myocardial infarction patients ...
Paschalis Karakasis   +9 more
doaj   +2 more sources

Comparative effectiveness and safety of vernakalant, flecainide, and amiodarone for atrial fibrillation cardioversion: a propensity score–matched analysis [PDF]

open access: yesBMC Emergency Medicine
Background Vernakalant is approved in Europe, Canada, and several Asian countries for the pharmacological cardioversion of recent-onset atrial fibrillation (AF), but remains unauthorized in the United States due to FDA safety concerns.
Giuseppe Dominijanni   +5 more
doaj   +2 more sources

Left atrial strain compared to volume in long-term flecainide treated patients with atrial fibrillation – a retrospective cohort study [PDF]

open access: yesBMC Cardiovascular Disorders
Background Left atrial volume index (LAVI) is associated with recurrent atrial fibrillation (AF) during flecainide treatment. Nevertheless, AF patients with normal LAVI experience rhythm control failure.
Alexander Siotis   +2 more
doaj   +2 more sources

Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells

open access: yesFrontiers in Pharmacology, 2023
Background and purpose: While flecainide is now an accepted treatment for arrhythmias associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), its mechanism of action remains controversial.
Emma J. Steer   +5 more
doaj   +1 more source

Maternal, fetal, neonatal and breastmilk flecainide concentration during maternal therapy and lactation: a case report

open access: yesInternational Breastfeeding Journal, 2023
Background Mothers requiring the antiarrhythmic agent flecainide are often advised not to breastfeed, because of the lack of data concercing neonatal effects and flecainide plasma concentrations following maternal exposure as well as via lactation.
Johanna A. van der Zande   +3 more
doaj   +1 more source

Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia

open access: yesFrontiers in Pediatrics, 2023
Flecainide is a class IC antiarrhythmic utilized in prophylaxis of refractory paroxysmal supraventricular tachycardias in pediatric populations. Despite being a highly effective agent, its narrow therapeutic index increases the risk of toxicity and ...
Ronald Palmen   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy